Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; Role in transport across the placenta

AIDS

Volumn 28, Issue 1, 2014, Pages 9-17

  Neumanova, Zuzana ^a   Cerveny, Lukas ^a   Ceckova, Martina ^a   Staud, Frantisek ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Breast cancer resistance protein; Multidrug resistance associated protein 2; P glycoprotein; Pregnancy; Tenofovir; Tenofovir disoproxil fumarate; Transplacental pharmacokinetics

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; TENOFOVIR; TENOFOVIR DISOPROXIL; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PHOSPHONIC ACID DERIVATIVE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG TRANSPORT; FEMALE; HUMAN; IN VITRO STUDY; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; METABOLISM; WISTAR RAT;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; FEMALE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANOPHOSPHONATES; P-GLYCOPROTEIN; P-GLYCOPROTEINS; RATS; RATS, WISTAR;

EID: 84892169927     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000112     Document Type: Article

References (43)

1. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector progress towards Universal Access Progress report 2011 (WHO, UNAIDS, UNICEF) http://whqlibdoc.who.int/pub lications/2011/9789241502986-eng.pdf. [Accessed on 13 June 2013].
2. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Recommendations for a public health approach (2010 version) http://whqlibdoc. who.int/publications/2010/9789241599818-eng.pdf. [Accessed on 29 May 2013].
3. Cavarelli M, Scarlatti G. Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies. J Intern Med 2011; 270:561-579.
4. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision http://whqlibdoc. who.int/publications/2010/9789241599764-eng.pdf. [Accessed on 7 April 2013].
5. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al. Antiretroviral treatment in pregnancy: a sixyear perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009; 23:513-520.
6. Griner R, Williams PL, Read JS, Seage GR 3rd, Crain M, Yogev R, et al. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS 2011; 25:385-394.
7. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab 2009; 10:520-529.
8. Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target 2012; 20:736-763.
9. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 2006; 22:400-410.
10. Hahnova-Cygalova L, Ceckova M, Staud F. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab Rev 2011; 43:53-68.
11. Meyerzu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 2005; 33:896-904.
12. Gulati A, Gerk PM. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J Pharm Sci 2009; 98:2317-2335.
13. Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 2012; 51:639-659.
14. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50:3297-3304.
15. Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007; 12:267-272.
16. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and nonnucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35:340-344.
17. van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002; 30:924-930.
18. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51:3498-3504.
19. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73:1573-1581.
20. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijns P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005; 35:1055-1066.
21. Cerveny L, Pavek P, Malakova J, Staud F, Fendrich Z. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia 2006; 47:461-468.
22. Poller B, Wagenaar E, Tang SC, Schinkel AH. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 2011; 8:571-582.
23. Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, et al. Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 2006; 319:53-62.
24. Cygalova LH, Hofman J, Ceckova M, Staud F. Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther 2009; 331:1118-1125.
25. Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 2010; 386:216-220.
26. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48:e108-e116.
27. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006; 34:786-792.
28. de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci 2009; 98:4413-4419.
29. Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 2007; 35:2076-2085.
30. Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 2007; 339:139-147.
31. Janneh O, Bray PG, Jones E, Wyen C, Chiba P, Back DJ, et al. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2011; 65:906-916.
32. Ahmadimoghaddam D, Hofman J, Zemankova L, Nachtigal P, Dolezelova E, Cerveny L, et al. Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPPR in rat. Toxicol Sci 2012; 128: 471-481.
33. Pavek P, Staud F, Fendrich Z, Sklenarova H, Libra A, Novotna M, et al. Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123. J Pharmacol Exp Ther 2003; 305:1239-1250.
34. Stulc J, Stulcova B, Sibley CP. Mechanisms of the fetomaternal transfer of NaR across the dually perfused placenta of the rat. Placenta 1995; 16:127-135.
35. Jakoubek V, Bibova J, Herget J, Hampl V. Chronic hypoxia increases fetoplacental vascular resistance and vasoconstrictor reactivity in the rat. Am J Physiol Heart Circ Physiol 2008; 294:H1638-1644.
36. Nirogi R, Bhyrapuneni G, Kandikere V, Muddana N, Saralaya R, Komarneni P, et al. Pharmacokinetic profiling of efavirenzemtricitabine-tenofovir fixed dose combination in pregnant and nonpregnant rats. BiopharmDrug Dispos 2012; 33:265-277.
37. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. Pharmacokinetics and bioavailability of the antihuman immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy) propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998; 42:687-690.
38. Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res 2006; 3:1.
39. Best BM, Letendre SL, Koopmans P, Rossi SS, Clifford DB, Collier AC, et al. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 2012; 59:376-381.
40. Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2- (phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14:1824-1829.
41. Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31: 22-35.
42. Camus M, Delomenie C, Didier N, Faye A, Gil S, Dauge MC, et al. Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta 2006; 27:699-706.
43. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL, Hankins GD, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2011; 79:921-925.